SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Guise TA, Mundy GR. Cancer and bone. Endocr Rev. 1998; 19: 1855.
  • 2
    Case records of the Massachusetts General Hospital (case 29–1972). N Engl J Med. 1972; 287: 138143.
  • 3
    Paling MR. Pope TL. Computed tomography of isolated osteoblastic colon metastases in the bony pelvis. J Comput Tomogr. 1988; 12: 203207.
  • 4
    Kingston JE, Plowman PN, Smith BF, Garvan NJ. Differentiated astrocytoma with osteoblastic skeletal metastases in a child. Childs Nervous System. 1986; 2: 219221.
  • 5
    Gamis AS, Egelhoff J, Roloson G, et al. Diffuse bony metastases at presentation in a child with glioblastoma multiforme. A case report. Cancer. 1990; 66: 180184.
  • 6
    McLennan MK. Case report 657: malignant epithelial thymoma with osteoblastic metastases. Skeletal Radiol. 1991; 20: 141144.
  • 7
    Giordano N, Nardi P, Vigni P, Palumbo F, Battisti E, Gennari C. Osteoblastic metastases from carcinoid tumor [letter]. Clin Exp Rheumatol. 1994; 12: 228229.
  • 8
    Liaw CC, Ho YS, Koon-Kwan NG, Chen TL, Tzann WC. Nasopharyngeal carcinoma with brain metastasis: a case report. J Neurooncol. 1994; 22: 227230.
  • 9
    Pingi A, Trasimeni G, Di Biasi C,et al. Diffuse leptomeningeal gliomatosis with osteoblastic metastases and no evidence of intraaxial lesions. Am J Neuroradiol. 1995; 16: 10181020.
  • 10
    Pederson RT, Haidak DJ, Ferris RA, Macdonald JS, Schein PS. Osteoblastic bone metastasis in Zollinger-Ellison syndrome. Radiology. 1976; 118: 6364.
  • 11
    George J, Lai FM. Metastatic cervical carcinoma presenting as psoas abscess and osteoblastic and lytic bony metastases. Singapore Med J. 1995; 36: 224227.
  • 12
    Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol. 1995; 18: 5164.
  • 13
    Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM, Meunier PJ. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer. 1983; 51: 918924.
  • 14
    Achbarou A, Kaiser S, Tremblay G, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 1994; 54: 23722377.
  • 15
    Thalmann GN, Anezinis PE, Chang S, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994; 54: 577581.
  • 16
    Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 1996; 56: 40964102.
  • 17
    Nelson JB, Lee WH, Nguyen SH, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996; 56: 663668.
  • 18
    Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995; 1: 944949.
  • 19
    Nelson JB, Nguyen SH, Wu-Wong JR, et al. New bone formation in an osteoblastic tumor model is increased by ET-1 overexpression and decreased by ETA receptor blockade. Urology. 1999; 53: 20632069.
  • 20
    Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate specific antigen (PSA) is an insulin-like growth factor binding protein-3 (IGFBP-3) protease found in seminal plasma. J Clin Endocrinol Metab. 1992; 75: 10461053.
  • 21
    Conover CA, Perry JE, Tindall DJ. Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J Clin Endocrinol Metab. 1995; 80: 987993.
  • 22
    Koutsilieris M, Frenette G, Lazure C, Lehoux JG, Govindan MV, Polychronakos C. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res. 1993; 13: 481486.
  • 23
    Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab. 1993; 76: 10311035.
  • 24
    Kanety H, Madjar Y, Dagan Y, et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab. 1993; 77: 229233.
  • 25
    Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab. 1996; 81: 411420.
  • 26
    Koutsilieris M, Polychronakos C. Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. Anticancer Res. 1992; 12: 905910.
  • 27
    Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res. 2002; 62: 917923.
  • 28
    Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332: 411415.
  • 29
    Levin ER. Endothelins. N England J Med. 1995; 333: 356365.
  • 30
    Stern PH, Tatrai A, Semler DE, et al. Endothelin receptors, second messengers, and actions in bone. J Nutr. 1995; 125 (Suppl): 2028S2032S.
  • 31
    Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 1994; 368: 703710.
  • 32
    Clouthier DE, Williams SC, Yanagisawa H, Wieduwilt M, Richardson JA, Yanagisawa M. Signaling pathways crucial for craniofacial development revealed by endothelin-A receptor-deficient mice. Dev Biol. 2000; 217: 1024.
  • 33
    Sasaki T, Hong MH. Endothelin-1 localization in bone cells and vascular endothelial cells in rat bone marrow. Anat Rec. 1993; 237: 332337.
  • 34
    Sasaki T, Hong MH. Localization of endothelin-1 in the osteoclast. J Electron Microsc 1993; 42: 193196.
  • 35
    Takuwa Y, Masaki T, Yamashita K. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun. 1990; 170: 9981005.
  • 36
    Kitten AM, Andrews CJ. Endothelin-1 expression in long-term culture of fetal rat calvarial osteoblasts: regulation by BMP-7. J Cell Physiol. 2001; 187: 218225.
  • 37
    Kitten AM, Harvey SA, Criscimagna N, Asher M, Lee JC, Olson MS. Osteogenic protein-1 downregulates endothelin A receptors in primary rat osteoblasts. Am J Physiol. 1997; 272 (6 Pt 1): E967E975.
  • 38
    Masukawa H, Miura Y, Sato I, Oiso Y, Suzuki A. Stimulatory effect of endothelin-1 on Na-dependent phosphate transport and its signaling mechanism in osteoblast-like cells. J Cell Biochem. 2001; 83: 4755.
  • 39
    Shioide M, Noda M. Endothelin modulates osteopontin and osteocalcin messenger ribonucleic acid expression in rat osteoblastic osteosarcoma cells. J Cell Biochem. 1993; 53: 176180.
  • 40
    Kitano Y, Kurihara H, Kurihara Y, et al. Gene expression of bone matrix proteins and endothelin receptors in endothelin-1-deficient mice revealed by in situ hybridization. J Bone Miner Res. 1998; 13: 237244.
  • 41
    Alam AS, Gallagher A, Shankar V, et al. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. Endocrinology 1992; 130: 36173624.
  • 42
    Tatrai A, Foster S, Lakatos P, Shankar G, Stern PH. Endothelin-1 actions on resorption, collagen and noncollagen protein synthesis, and phosphatidylinositol turnover in bone organ cultures. Endocrinology 1992; 131: 603607.
  • 43
    Kimmel CB, Miller CT, Moens CB. Specification and morphogenesis of the zebrafish larval head skeleton. Dev Biol. 2001; 233: 239257.
  • 44
    Kinoshita A, Tamura T, Aoki C, et al. Demonstration of endothelin (ET) receptors on cultured rabbit chondrocytes and stimulation of DNA synthesis and calcium influx by ET-1 via its receptors. Cell Biol Int. 1995; 19: 647654.
  • 45
    Lodhi KM, Sakaguchi H, Hirose S, Shibabe S, Hagiwara H. Perichondrial localization of ETA receptor in rat tracheal and xiphoid cartilage and in fetal rat epiphysis. Am J Physiol. 1995; 268 (2 Pt 1): C496C502.
  • 46
    Del Bufalo D, Di Castro V, Biroccio A, et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol. 2002; 61: 524532.
  • 47
    Rosano L, Varmi M, Salani D, et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. 2001; 61: 83408346.
  • 48
    Asham E, Shankar A, Loizidou M, et al. Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer. 2001; 85: 17591763.
  • 49
    Granchi S, Brocchi S, Bonaccorsi L, et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate. 2001; 49: 267277.
  • 50
    Le Brun G, Aubin P, Soliman H, et al. Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. Cytokine. 1999; 11: 157162.
  • 51
    Chiao JW, Moonga BS, Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer. 2000; 83: 360365.
  • 52
    Patel KV, Schrey MP. Human breast cancer cells contain a phosphoramidon-sensitive metalloproteinase which can process exogenous big endothelin-1 to endothelin-1: a proposed mitogen for human breast fibroblasts. Br J Cancer. 1995; 71: 442447.
  • 53
    Yorimitsu K, Moroi K, Inagaki N, et al. Cloning and sequencing of a human endothelin converting enzyme in renal adenocarcinoma (ACHN) cells producing endothelin-2. Biochem Biophy Res Commun. 1995; 208: 721727.
  • 54
    Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in breast cancer mediated-osteolysis. J Clin Invest. 1996; 98: 15441549.
  • 55
    Yin JJ, Selander KS, Chirgwin JM, et al. TGFβ signaling blockade inhibits parathyroid hormone-related protein secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999; 103: 197206.
  • 56
    Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999; 286: 19461949.
  • 57
    Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther. 1996; 276: 473481.
  • 58
    Von Geldern TW, Tasker AS, Sorensen BK, et al. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ETB selectivity. J Med Chem. 1999; 42: 36683678.
  • 59
    Jae H-S, Winn M, Dixon DB, et al. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists. J Med Chem. 1997; 40: 32173227.
  • 60
    Stephenson J. Experimental prostate cancer drugs slow disease progression. J Am Med Assoc. 2001; 4; 286:34.
  • 61
    Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol. 2002; 20: 21712180.